Cargando…

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma

Detalles Bibliográficos
Autores principales:	Vazquez, Sara E., Bastard, Paul, Kelly, Kathleen, Gervais, Adrian, Norris, Philip J., Dumont, Larry J., Casanova, Jean-Laurent, Anderson, Mark S., DeRisi, Joseph L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132742/ https://www.ncbi.nlm.nih.gov/pubmed/34009544 http://dx.doi.org/10.1007/s10875-021-01060-0

Ejemplares similares

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality
por: Troya, Jesús, et al.
Publicado: (2022)

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19
por: van der Wijst, Monique G. P., et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients
por: Koning, Rutger, et al.
Publicado: (2021)

Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure
por: Ghale, Rajani, et al.
Publicado: (2022)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Human autoantibodies underlying infectious diseases
por: Puel, Anne, et al.
Publicado: (2022)

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
por: Bastard, Paul, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

Auto-anticorps anti-interférons de type I et COVID-19 sévère
por: Bastard, Paul, et al.
Publicado: (2021)

Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis
por: Arango-Franco, Carlos A., et al.
Publicado: (2023)

Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19: Anti-IFN antibodies in critical COVID-19 correlate with poor ISG response and upregulation of LAIR1 surface protein in PBMCs
por: van der Wijst, Monique G.P., et al.
Publicado: (2021)

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona
por: Solanich, Xavier, et al.
Publicado: (2021)

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
por: Borsani, Oscar, et al.
Publicado: (2021)

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2022)

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia
por: de Prost, Nicolas, et al.
Publicado: (2021)

Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
por: Kacar, Mark, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Neutralizing Anti-Cytokine Autoantibodies Against Interferon-α in Immunodysregulation Polyendocrinopathy Enteropathy X-Linked
por: Rosenberg, Jacob M., et al.
Publicado: (2018)

Type I interferons and SARS-CoV-2: from cells to organisms
por: Bastard, Paul, et al.
Publicado: (2022)

Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors
por: Gomaa, Mokhtar R., et al.
Publicado: (2020)

Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains
por: Yasamut, Umpa, et al.
Publicado: (2019)

Diagnostic and Therapeutic Challenges in Disseminated Mycobacterium colombiense Infection Caused by Interferon-γ Neutralizing Autoantibodies
por: Matono, Takashi, et al.
Publicado: (2023)

Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies
por: Wolff, Anette S.B., et al.
Publicado: (2023)

Impaired thymic AIRE expression underlies autoantibodies against type I IFNs in humans with inborn errors of the alternative NF-κB pathway
por: Voyer, Tom Le, et al.
Publicado: (2023)

Autoantibodies to Interferons in Infectious Diseases
por: Quiros-Roldan, Eugenia, et al.
Publicado: (2023)

450. Type I Interferon Autoantibodies Are Detected in Those with Critical COVID-19, Including a Young Female Patient
por: Yee, Debra, et al.
Publicado: (2021)

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
por: Mor, Michael, et al.
Publicado: (2021)

Autoantibody discovery across monogenic, acquired, and COVID19-associated autoimmunity with scalable PhIP-Seq
por: Vazquez, Sara E, et al.
Publicado: (2022)

Disseminated Mycobacterium avium Infection Presenting with Bladder Lesions in a Patient with Interferon-γ-neutralizing Autoantibodies
por: Miyashita, Koichi, et al.
Publicado: (2018)

Disseminated Mycobacterium avium Infection Complicated with Chylous Ascites in a Patient with Neutralizing Autoantibodies to Interferon-γ
por: Yamaba, Yusuke, et al.
Publicado: (2020)

Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients
por: Gervais, Adrian, et al.
Publicado: (2023)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
por: Kroemer, Marie, et al.
Publicado: (2022)

A non-HIV case with disseminated Mycobacterium kansasii disease associated with strong neutralizing autoantibody to interferon-γ
por: Nei, Takahito, et al.
Publicado: (2012)

Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections
por: Chi, Chih-Yu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k5sin000nn7hj8j6o97ufaiq0m